In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation (vol 123, pg 85, 2017)

被引：1
|
作者：
Sager, Jennifer E. [1 ]
Tripathy, Sasmita [1 ]
Price, Lauren S. L. [1 ]
Nath, Abhinav [2 ]
Chang, Justine [3 ]
Stephenson-Famy, Alyssa [3 ]
Isoherranen, Nina [1 ]
机构：
[1] Univ Washington, Sch Pharm, Dept Pharmaceut, Seattle, WA 98195 USA
[2] Univ Washington, Sch Pharm, Dept Med Chem, Seattle, WA 98195 USA
[3] Univ Washington, Sch Med, Dept Obstet & Gynecol, Seattle, WA 98195 USA
来源：
BIOCHEMICAL PHARMACOLOGY | 2021年 / 183卷
关键词：
D O I：
10.1016/j.bcp.2020.114306
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation
    Sager, Jennifer E.
    Tripathy, Sasmita
    Price, Lauren S. L.
    Nath, Abhinav
    Chang, Justine
    Stephenson-Famy, Alyssa
    Isoherranen, Nina
    BIOCHEMICAL PHARMACOLOGY, 2017, 123 : 85 - 96
  • [2] Inhibition of CYP2D6 activity by bupropion
    Kotlyar, M
    Brauer, LH
    Tracy, TS
    Hatsukami, DK
    Harris, J
    Bronars, CA
    Adson, DE
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2005, 25 (03) : 226 - 229
  • [3] CYP2D6 INHIBITION BY BUPROPION AND ITS METABOLITES IS STEREOSPECIFIC AND CIRCULATING METABOLITES ACCURATELY PREDICT CLINICAL BUPROPION-CYP2D6 INTERACTION.
    Tanaudommongkon, I.
    Gufford, B. T.
    Lu, J. B.
    Desta, Z.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S113 - S113
  • [4] Database analyses for drug-drug interactions involving CYP2D6 inhibition
    Ito, K
    Hallifax, D
    Obach, RS
    Houston, JB
    DRUG METABOLISM REVIEWS, 2003, 35 : 49 - 49
  • [5] CYP2D6 Genotype Phenotype Discordance Due to Drug-Drug Interaction
    Monte, Andrew A.
    West, Kelsey
    McDaniel, Kyle T.
    Flaten, Hania K.
    Saben, Jessica
    Shelton, Shelby
    Abdelmawla, Farah
    Bushman, Lane R.
    Williamson, Kayla
    Abbott, Diana
    Anderson, Peter L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 104 (05) : 933 - 939
  • [6] Methodological Considerations on CYP2D6 Phenoconversion Due to Drug-Drug Interaction
    Ziesenitz, Victoria C.
    Mikus, Gerd
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 (05) : 1076 - 1076
  • [7] CYP2D6 "humanized" mice: A model for in vivo pharmacokinetics and drug-drug interactions
    Corchero, J
    Pimprale, S
    Krausz, K
    Gelboin, HV
    Gonzalez, J
    FASEB JOURNAL, 2000, 14 (08): : A1437 - A1437
  • [8] The Effect of CYP2D6 Drug-Drug Interactions on Hydrocodone Efficacy
    Monte, A. A.
    Heard, K. J.
    Campbell, J.
    Weinshilboum, R. M.
    Vasiliou, V.
    ANNALS OF EMERGENCY MEDICINE, 2013, 62 (04) : S158 - S159
  • [9] The Effect of CYP2D6 Drug-Drug Interactions on Hydrocodone Effectiveness
    Monte, Andrew A.
    Heard, Kennon J.
    Campbell, Jenny
    Hamamura, D.
    Weinshilboum, Richard M.
    Vasiliou, Vasilis
    ACADEMIC EMERGENCY MEDICINE, 2014, 21 (08) : 879 - 885
  • [10] Drug-drug interaction between hydroxybupropion and venlafaxine - a pharmacokinetic study on CYP2D6
    Zioris, G.
    Warrings, B.
    Heiduk, S.
    Deckert, J.
    Unterecker, S.
    Scherf-Clavel, M.
    PHARMACOPSYCHIATRY, 2024, 57 (02) : 92 - 92
12345